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REPRESENTATION AND COMMUNICATION OF PHARMACEUTICAL EXPERT INFORMATION
M. Wagner
Institute for Medical Statistics and Documentation, University of Mainz, Germany
8th European Conference on Information Systems, Vienna, Austria, July 2000
Abstract - Pharmaceutical expert information is
characterized by steady increase in extent and complexity as well as by strong interweavement and
penetration with interdependent references. These
properties suggest the utilization of modern hypermedia technology, organizing knowledge as a network of linked pieces, enabling more intuitive,
faster and easier navigation within the growing
information space. There is a need for a suitable,
role oriented external representation of pharmaceutical expert information.
The application of pharmaceutical expert information when analyzing medications for contraindications and interactions is mainly mechanical in
nature. It requires to follow references and to compare codes. The electronic availability of medication information, which is often forced by drug
dispensing systems, is not exhausted when these
procedures are performed manually at the screen.
There is a need for automatization of these procedures. This automatization requires a suitable internal representation of pharmaceutical expert information.
The universality of pharmaceutical information
systems leaves open their conceptual environment.
The different kinds of application scenarios pose
strong requirements on the formalization of expert
information. A universal representation has to be
found which captures the nature of pharmaceuticals
including common properties of drug classification
systems. The diversity of the latters within the different healthcare organisations is to be regarded as
the most serious barrier aggravating global communication within the healthcare system.
I. MOTIVATION
The main concern of healthcare management has
ever been embodied by two conflicting goals. These
are improving care quality while reducing care
costs. Information technology already has proven
its positive impact on both goals. While general
administrative tasks are being performed more
efficiently for some decades, expert oriented systems are entering the medical domain with increasing support capabilities for domain specific therapeutic procedures leading to more secure and efficient therapy planning, monitoring and control.

The demands on quality and effectiveness of care
are posed by social, legal and political areas, resulting in growing expectation, uncertainty and pressure concerning health care professionals’ use of
expert information. These circumstances are cornering medical practitioners. A variety of role specific
information problems may be identified which
finally can be attributed to the non-availability of
suitable represented expert information as well as to
missing automatization of medical procedures. In
their entirety they indicate two major information
problems in healthcare.
The representation problem consists of the lack of a
universal representation of pharmaceuticals which
formally describes their common properties as well
as their behavior within groups of simultaneously
applied drugs. Internal representation affects granularity and precision of information as well as the
functionality of the application system. External
representation affects suitability of access and navigation mechanisms, which depend on the user’s role
and situation. An internal representation may meet
the needs of many applications, while an external
representation can only be as suitable as the internal
representation allows.
The communication problem refers to the communication capabilities of a representation delivered
by a solution of the previous problem. There is
nearly no benefit of a pharmaceutical information
model if information is not suitable for transportation. This means that the impact of an internal representation reaches interorganizational cooperation
capabilities. This affects particularly the diversity
of semantic reference systems used by local representations. The communication problem consists of
finding means to enable organizations to exchange
information with a minimum of human intervention.
As the information jungle continues to grow healthcare costs and treatment quality change to worse.
The patient has to bear the consequences. While his
contribution on treatment costs increases, no one
can guarantee that the medication designed by the
physician is optimal in both therapeutic and economic sense. For instance, many expensive commercial brand products of major manufacturers may
be substituted by more beneficial, therapeutically
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equivalent generics, but without this information at
his fingertips the physician will continue to prescribe products with concise and habitual names.
II. APPLICATION DOMAIN
The application domain targeted by pharmaceutical
information systems includes any medical subject
area affected by information on properties of pharmaceutical products. This comprises the treatment
situation at the physician’s desktop, drug dispensing
procedures in hospital pharmacies, pharmaceutical
consultation at the drugstore as well as patient
home information. Although differences exist
among role and situation specific external representations of user oriented information, any application
of pharmaceutical information systems relates to
some properties of pharmaceuticals.
This universal applicability of pharmaceutical information systems leads to their architectural role
as a subsystem within a not further specified superordinated medical information system. Many
applications may exist. Thus, these systems are
highly polymorphic in nature and the need for a
single universal internal representation can be justified with reusability, integrity and universality. The
role leaves open any assumptions of the application
domain. Any usage is specific to the superordinated
application system. However, three principle applications of pharmaceutical information systems may
be considered.
Medication Analysis is a procedure that aims to
identify any critical problems within a given input
medication. A set of problems is computed, each of
which may be a contra-indication, an interaction or
an overdose. It is desirable that this procedure also
adds links to further information found in local or
external documents. Medication analysis can significantly improve security of drug dispensation.
Medication Transformation is a procedure that aims
to construct a new medication which is therapeutically equivalent to an input medication, and which
meets certain optimization criteria. The most beneficial criteria refer to cost reduction. Then, some of
the prescribed drugs are substituted with the most
beneficial but therapeutically equivalent products
available. This procedure relates to Managed Care
(Prescription Benefit Management), as is practiced
in the United States as an intervention of insurance
companies in the prescriptions of physicians. Medication transformation can significantly improve
prescription efficiency.
Medication Synthesis is a procedure that aims to
construct a medication based on its desired proper-

ties. The input is a specification of these properties
in terms of wanted and optionally unwanted effects,
and the output is a medication with a maximum of
conformity with the specification and a minimum
of undesired properties, concerning both therapeutic
and economic issues. Until now, medication analysis is to be regarded as a theoretical application and
is mentioned because it formally is the opposite
procedure to medication analysis.
The application goal for the physician seems to be
clear: The goal is to be able to define an optimal
medication for a patient with a given disease within
a given situation. In this context the term ’optimal’
refers to both the therapeutic suitability and the
economic effectiveness of a medication. While this
task is impossible to accomplish manually in reasonable time, distributed information services could
provide techniques to compare costs and therapeutic properties of pharmaceutical products automatically. For instance, the physician could select some
brand drug and ask for any generics with the same
composition and effects.
Within the scope of a hospital pharmacy two principal uses of pharmaceutical expert information
may be distinguished. The main purpose is the drug
dispension, usually performed automatically by a
machine controlled by a special software system.
Up to date this is the primary reason for electronic
representation of medication information. The second task of the pharmacy is to check each medication for certain errors and inconsistencies, e. g.
contra-indications or serious interactions. This
analysis, which is regular and mechanical in nature,
is still done manually. Pharmacists sit in front of the
screen and analyze medications using a book. There
is a need for the automatization of medication
analysis.
From the patient’s point of view there is a need for
information on the drugs he takes, on their usage
and influence on his disease. This information has
to be presented in a way understandable by the
patient. This means that descriptions and instructions should not contain expert terminology and
should not require a deeper understanding of the
medical domain. This property of presentation has
great influence on the patient’s discipline. Apart
from medical or scientific oriented scales, good
patient information must be regarded as one component of a good therapy.
For any expert oriented application it is desirable to
access local and external documents, which are
relevant to a given situation or which explain some
statement made by a system. For instance, if medication analysis reports a critical interaction, links

search

should also be presented allowing the user to immediately access further information from standard
literature or product documentation. This also suggests an application for medical students where a
system can analyze their prescriptions and generate
hints and advices.
III. PROBLEMS OF INFORMATION MANAGEMENT
Healthcare in general is characterized by high specialization and division of labour. Many professionals practice services for many patients, and data
is produced at many places and may be needed at
many others. Mobility of patients and the free
choice of medical practitioner makes this situation
worse, as the individual’s moves through the healthcare system leave trails consisting of distributed
heterogeneous medical data. Thus, mobility of
patients requires the mobility of data.
Pharmaceutical product information is distributed
and heterogeneous in a similar way as is patient
data. Furthermore, it is subject to fast change and
reconditioning. It partly refers to patient medical
data, as is with contra-indications or age specific
dosage instructions. As a conclusion one may notice strong interconnections and dependencies between patient specific medical data and pharmaceutical product information. Product documentation
refers to patient specific conditions, and patient
therapy documentation refers to applied products.
The scattering and heterogenity of both patient
history data and pharmaceutical product information lead to a variety of information problems for
the different actors in the healthcare system. These
problems refer to the availability of information in
general and to the suitability of its representation in
particular. Any of these role specific information
problems may finally be attributed to the two major
problems of healthcare information management:
representation and communication of expert and
product information.
The physician’s information problem refers to the
treatment situation, where medications are composed and pharmaceutical products are compared.
Far too much information would have to be taken
into account in order to determine the most effective drugs regarding to both therapeutic suitability
and economic benefit. The problem consists of not
having means to consult all of the available information sources manually, without the help of information technology.
The pharmaceutical company’s information problem refers to both the communication of product
information to the practitioners who prescribe it and

the reflow of information gained through observation and experience. There are incentives for the
industry to pass actual findings delivered by research and practice to the practitioners. There are
also incentives to get informed on unknown drug
effects.
The insurance company’s information problem
refers to the economic optimization of prescriptions
through substitution of products. Under care and
attention of the critical constraint of therapeutic
equivalence the substitution of brand products with
generics bears a high potential of cost saving but
effect keeping transformation. But this transformation requires knowledge and is desired to be performed automatically.
The patient’s information problem refers to his
situation at home, after being undeceived and instructed concerning drug application by the physician. In general, additional questions arise within
this situation and many aspects on disease, treatment, medication and instructions are not covered
by the short and expensive consultation. From the
patient’s point of view there is a need to be able to
get informed on these aspects whenever he wants
to. From the physician’s point of view there also is a
need to delegate standard explanations to public
media.
In the advent of the approaching information age
these information problems would not exist, if there
were reasonable means of applying information
technology on the use of pharmaceutical expert
information. This leads to the very question of
information exchangeability within the healthcare
sector regarding to pharmaceutical products. As
with any other kind of information on entities, the
attributes of which are represented as references
into certain external classifications, drug information may only be interpreted in regard to respective
semantic reference systems.
There is one major conclusion to be drawn from the
variety of role specific information problems illustrated above. They have in common the need for
information retrieval and processing concerning
pharmaceutical products as well as its preparation
in a suitable external representation. It seems that
the reason for missing availability of pharmaceutical information is not its absence but the different
languages existing in healthcare. Starting from that
today there are means to transport information from
one site to another, one may realize that the problem cannot be the absence of communication infrastructures. The answer is much more simple and
complex at the same time: The problem lays within
the information itself. The most serious problem
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blocking global communication in healthcare results from the lack of common languages.
IV. MODELING
INFORMATION

PHARMACEUTICAL

EXPERT

The formation of a universal information model for
pharmaceutical products and their properties relates
to domain specific coherencies concerning drugs
and chemical substances as well as many aspects of
software engineering in general. The former involves some understanding of the applications and
effects of pharmaceuticals as well as the interdependencies among the different kinds of properties
a drug may have. The latter involves design strategies and modeling techniques which meet today’s
requirements on compactness, reusability, flexibility and consistency of an internal representation.
Any pharmaceutical information model will be
measured by its applicability in both fields.
The most fundamental awareness of any drug characteristics describing information model must be
the distinction of two kinds of properties which
may be regarded in different layers. These are
properties, which refer to a pharmaceutical product
in isolation, on the one hand, and its behavior
within the society of a group of drugs, on the other
hand. The former are constant for a drug and will
not change. The latter depends on the combination
of drugs, the patient’s state and on many other aspects of its situation. This distinction may be captioned by the following assignments.
Static pharmaceutical information refers to drug
properties which will not change when the drug’s
role within a medication or therapy changes. These
properties include name, manufacturer, composition
as well as obligatory information. Some of these
properties may be represented as isolated data elements. This means that they are consistent on their
own, and their interpretation is independent of certain external formalisms. Other properties (e. g.
indications) are to be regarded as references into
external semantic reference systems, and may not
be interpreted without the awareness of these formalisms. For instance, an indication can be regarded as a reference into an indication classification system. Of course one could model such properties as simple text fields. But in this case, only
humans could understand this information.
Dynamic pharmaceutical information refers to drug
characteristics concerning their behavior within a
medication, especially the interplay of therapeutic
effects. These characteristics are dynamic in nature
because they may change with a drug’s membership

within different medications. They depend on various parameters of a clinical situation, including
disease, patient demographic data, and, of course,
other prescriptions. A drug may change the effect
of other drugs and its effects may be changed by
others.
A universal pharmaceutical information model
should not refer to some specific classification
system. Instead, it should refer to an abstract metastructure which is capable of being instantiated by
any classification. Groupings, as such metastructures will be called in the following, are abstract trees representing inheritance hierarchies with
implicit IS-A semantics. Inheritance is the principal
property these structures provide: Any information
associated with some group is also valid for each of
its subgroups.
The universality of a pharmaceutical information
model results from two major design properties.
First, not one but a set of groupings reside in the
knowledge base, providing a language for describing drug properties. Secondly, any drug may be
assigned into not one but into any number of groups
belonging to different groupings. The first design
issue (multiple groupings) allows the consideration
of different classification strategies and therefore
the provision for different applications. Each grouping represents some specific view on the domain,
focussing specific attributes of pharmaceutical
products. The second design issue (multiple assignments) allows a maximum of precision concerning the representation of drug properties. One
single assignment represents some feature of a
drug. The entirety of assignments characterizes a
drug.
Groupings provide the vocabulary to specify relations between groups of drugs. Conflicts may be
defined which relate one group to another and state
that a combination of respective group members
may cause a critical interaction. Additional conditions may be attached to such a conflict (e. g. indication, dosage) that further refine the set of cases
where a conflict indicates an interaction. In this
way, medication analysis may be reduced to the
evaluation of group combinations.
Analytic processing capabilities of pharmaceutical
expert information belong to the most beneficial
properties a suitable information model can provide. Examples for their applications include automatic medication analysis, product comparison and
even medication analysis. There is no loss in functionality comparing to low structured representations, because simple text documents may always
be generated from precise representations. In addi-
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tion, such a generation may take respect to the
user’s role and situation through inclusion and exclusion of information components, detail level
determination and through terminology selection.
The universality of a pharmaceutical information
model based on the abstract grouping concept presented above may be illustrated by the following
scenario. Assume a hospital pharmacy which is
responsible for the daily validation of medication
information. The pharmacy uses their own drug
classification system which is tailored to the set of
locally applied pharmaceuticals. The automation of
medication analysis is desired on the condition that
the local classification system needs not to be replaced.
A medication analysis system based on the abstract
grouping model meets these requirements. It suggests the following installation steps. First, the local
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classification system is entered into the system as a
set of groups organized in a hierarchical structure.
Secondly, the set of drugs is acquired focussing on
static information and, thus, resulting in a linear list
of records. Then, drugs are characterized by assigning one or more groups to each drug. Finally, conflicts are defined by selecting sets of groups the
elements of which form a critical combination.
Then, medication analysis can be performed automatically. The system may be configured to let pass
standard medications and to identify occurrences of
critical drug combinations. In these cases the system may notify the users and the medication can be
reviewed manually. From the pharmacist’s point of
view, automatic medication analysis can significantly reduce the number of cases which need human attention, while the local classification system
can be used to specify the electronic knowledge
needed for medication analysis.

Substance
Drug

Drug

Groupings

Knowledge

Conflict

Conflict

Interplay between objects, groups and conflicts

Conflict
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V. FURTHER RESEARCH
The formation of a universal pharmaceutical information model may suggest an internal representation within the context of pharmaceutical information systems, but it cannot provide solutions for
problems resulting from the distinct roles, views
and interests among the different actors in the
healthcare system. Political agreement of common
organization of expert information cannot be concern of medical informatics.
The unification problem of healthcare refers to the
chasm between universality and specifity of semantic reference systems. A universal classification
system will not be suitable for specific applications
and a classification which is suitable for a specific
application will not be suitable for others. There
seems to be no way out: The unification of semantic reference systems appears to be the only solution.
The standardization problem refers to the development of semantic reference systems and to the institutionalization of their coordination. Starting from
that diversity exists between different applications,
roles and interests, it would be desirable to have
these differences controlled by a global institution.
The question is: Who will act as a global standards
defining institution and which interests will be
covered?
The major problem of internal drug representation
is the formation of a universal information model.
This in turn leads to the challenge of developing
one universal drug classification system. Since any
classification is a direct result of respective design
strategies and focused applications, a universal drug
classification system must be the result of common
design strategies and common goals. The question
is: What should be the major design strategy
regarding to a universal drug classification system?
The universality of scope claimed by uniformity of
representation leads to the property of suitability. A
universal classification system is exhaustive with
regard to the focused domain, and in all probability
it is oversized for small applications. This holds for
monoaxial classifications. There is no proof for the
theoretical existence of a universal (possibly multiaxial) classification which meets suitability of all
applications. The question is: Can a universal
pharmaceutical classification system meet the needs
of specialized applications?
In the past many innovative concepts were developed to help overcome information problems in
healthcare. Many projects failed at the requirements

of data security. The latter has emerged to a political rather than a technical barrier of healthcare
communication. In many cases, data security requirements for technical procedures exceed the
requirements for equivalent manual procedures. For
instance, the German electronic health insurance
card was originally intended to store medical data
on a patient’s history. Today these cards do not
contain any medical data. Under full agreement to
the importance of data security, the question is:
Will data security issues continue to barrier information processing and communication in healthcare?
Taking the diversity and heterogenity of pharmaceutical classification systems for granted and immutable one possibility remains. This is the automated mapping of semantic references between
different classification systems. This means that a
reference into some classification may be automatically translated into a reference into another classification. Since almost any pair of classification
trees consists of similar layers, such a translation is
always possible. However, information loss is the
price for this automated mapping, when differences
between classifications are too large.
VI. DISCUSSION
The two-sided challenge of representation and
communication of pharmaceutical product information illustrates the interdependency between information modeling and distribution in healthcare.
Both dimensions affect the application of expert
information. A pharmaceutical information model
may be suitable for some applications and it may be
suitable for communication. But it seems to be very
difficult to design a model which is suitable regarding both dimensions.
As with any kind of information which is used in
different application contexts, pharmaceutical
product information may be structured in many
ways, resulting in different and in most cases incompatible reference systems. Pharmaceuticals may
be classified by indication or contra-indication,
their composition of chemical substances, their
pharmacological effects or therapeutic use. Any of
these characteristics implicates certain applications
of the resulting classification. In general, a classification system incorporates an application specific
strategy of decomposition. Strong interdependencies exist among properties like universality, complexity and suitability.
These circumstances suggest doubts on the theoretical existence of a universal classification system
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for a knowledge domain covering all application
scenarios and meeting all requirements. These
doubts get stronger under the consideration of suitability, which correlates extent and complexity of a
classification system with extent and complexity of
an application scenario. For instance, the german
drug classification system provided by the ’Rote
Liste’ covers about 9000 commercial pharmaceutical products, while small hospital pharmacies deal
with only about 800 drugs, which in their combination cover all medications. It seems that a universal
classification system for a knowledge domain,
which is exhaustive in nature, must be oversized for
the needs of small applications.
A scientific point of view enlightens many aspects
of domain specific classification development
which identify the real problems predominantly
within the expert domain itself. Many applications
of classification systems make use of their hierarchical structure and object-oriented nature, if given.
In fact, properties of classifications are applied in
terms of inheritance and polymorphism. There exist
reasonable doubts on the awareness of the objectoriented modeling paradigm in the community of
classification developing medics. This can be
proved with several classifications developed in
medicine, which in general match the requirements
of knowledge representations, but fail at the vital
design properties (e. g. ICD, ICD-O, ATC).
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